Healthcare Most Volatile: OXiGENE (NASDAQ:OXGN), Celldex Therapeutics (NASDAQ:CLDX), Galectin Therapeutics (NASDAQ:GALT), Arrowhead Research (NASDAQ:ARWR)

OXiGENE Inc. (NASDAQ:OXGN) on Mar. 18 reported financial results for the year ended December 31, 2013. For the year ended December 31, 2013, OXiGENE reported a net loss of $8.3 million compared to a net loss of $8.1 million for the comparable period in 2012. OXiGENE Inc. (NASDAQ:OXGN) shares after opening at $3.47 moved to $3.80 on last trade day and at the end of the day closed at $3.75. Company price to sales ratio in past twelve months was calculated as 99.00 and price to cash ratio as 1.13. OXiGENE Inc. (NASDAQ:OXGN) showed a negative weekly performance of -6.48%.

Celldex Therapeutics (NASDAQ:CLDX) had its price objective raised by Jefferies Group from $29.00 to $31.00 in a research report released on Tuesday morning, Analyst Ratings News reports. Jefferies Group currently has a buy rating on the stock. Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares fell -4.99% in last trading session and ended the day on $18.85. CLDX return on equity ratio is recorded as -48.80% and its return on assets is -41.90%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) yearly performance is 71.05%.

Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced that on Monday, March 31, 2014, the Company will report results from the first cohort of its Phase 1 clinical trial examining GR-MD-02 in fatty liver disease (NASH) with advanced fibrosis. Galectin Therapeutics Inc. (NASDAQ:GALT) shares moved up 8.84% in last trading session and was closed at $15.88, while trading in range of $15.63 – $18.62. Galectin Therapeutics Inc. (NASDAQ:GALT) year to date (YTD) performance is 96.53%.

Deutsche Bank reiterated their buy rating on shares of Arrowhead Research Corp (NASDAQ:ARWR) in a research note released on Monday morning, Stock Ratings Network reports. Arrowhead Research Corp (NASDAQ:ARWR) weekly performance is -28.58%. On last trading day company shares ended up $17.22. Arrowhead Research Corp (NASDAQ:ARWR) distance from 50-day simple moving average (SMA50) is -7.11%. Analysts mean target price for the company is $28.75.